FDA panel to review Lilly's Olumiant

FDA's Arthritis Advisory Committee will meet on April 23 to discuss an NDA for Olumiant baricitinib (LY3009104) from Eli Lilly and Co. (NYSE:LLY) to treat moderately to severely active rheumatoid arthritis. Lilly resubmitted the NDA after receiving a complete response letter in April 2017 (see BioCentury, April 14, 2017).

Olumiant is approved in the EU and Japan to treat RA. The drug is a Janus kinase-1 (JAK-1) and JAK-2 inhibitor...